Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
07902199
ABSTRACT:
The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g., tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
REFERENCES:
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6469002 (2002-10-01), Ohshima et al.
patent: 6794379 (2004-09-01), Medina et al.
patent: 7417045 (2008-08-01), Anilkumar et al.
patent: 7566718 (2009-07-01), Wong et al.
patent: 2002/0018776 (2002-02-01), Hancock
patent: 2003/0055054 (2003-03-01), Medina et al.
patent: 2006/0036093 (2006-02-01), Lin et al.
patent: 2006/0276448 (2006-12-01), Zeng et al.
patent: 2006/0276457 (2006-12-01), Yu et al.
patent: 2006/0276479 (2006-12-01), Kim et al.
patent: 2007/0021611 (2007-01-01), McGuinness et al.
patent: 2007/0054919 (2007-03-01), Rosenblum et al.
patent: 2007/0082913 (2007-04-01), Kim et al.
patent: 2008/0039474 (2008-02-01), Rosenblum et al.
patent: 2008/0292589 (2008-11-01), Anilkumar et al.
patent: WO93/10091 (1993-05-01), None
patent: WO99/20606 (1999-04-01), None
patent: WO02/085861 (2002-10-01), None
patent: WO03/070242 (2003-08-01), None
patent: WO03/082335 (2003-10-01), None
patent: WO03/098185 (2003-11-01), None
patent: WO03/101970 (2003-12-01), None
patent: WO2004/074273 (2004-09-01), None
patent: WO2004/074278 (2004-09-01), None
patent: WO2004/074287 (2004-09-01), None
patent: WO2004/113323 (2004-12-01), None
patent: WO2005/077369 (2005-08-01), None
patent: WO2007/109238 (2007-09-01), None
patent: WO2008/079279 (2008-07-01), None
International Search Report for PCT/US2007/015924 dated Nov. 16, 2007.
Angiolilo, Anne L., et al.; “Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo”; The Journal of Experimental Medicine; 182:155-162 (1995).
Baggiolini, Marco, et al.; “Interleukin-8 and Related Chemotactic Cytokines—CXC and CC Chemokines”; Advances in Immunol.; 55:97-179 (1994).
Baggiolini, Marco, et al.; “CC chemokines in allergic inflammation”; Immunology Today; 15(3):127-133 (1994).
Clark-Lewis, Ian, et al.; “Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs”; The Journal of Biological Chemistry; 266(34):23128-23134 (1991).
Clark-Lewis, Ian, et al.; “Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg”; Proc. Natl. Acad. Sci. USA; 90:3574-3577 (1993).
Cole, Katherine E., et al.; “Interferon-inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3”; J. Exp. Med.; 187(12):2009-2021 (1998).
Farber, Joshua M.; “A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines”; Proc. Natl. Acad. Sci. USA; 87:5238-5242 (1990).
Farber, Joshua M.; “HuMIG: A New Human Member of the Chemokine Family of Cytokines”; Biochemical and Biophysical Research Communications; 192(1):223-230 (1993).
Galy, Anne H. M., et al.; “IL-1, IL-4, and IFN-γ Differentially Regulate Cytokine Production and Cell Surface Molecule Expression in Cultured Human Thymic Epithelial Cells”; The Journal of Immunology; 147(11):3823-3830 (1991).
Hebert, Caroline A., et al.; “Scanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Receptor Binding”; The Journal of Biological Chemistry; 266(28):18989-18994 (1991).
Liao, Fang, et al.; “Human Mig Chemokine: Biochemical and Functional Characterization”; J. Exp. Med.; 182:1301-1314 (1995).
Loetscher, Marcel, et al.; “Chemokine Receptor Specific for IP10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes”; J. Exp. Med.; 184:963-969 (1996).
Loetscher, Pius, et al.; “Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes”; FASEB J.; 8:1055-1060 (1994).
Luster, Andrew D., et al.; “IP-10, a-C-X-C- Chemokine, Elicits a Potent Thymus-dependent Antitumor Response In Vivo”; J. Exp. Med.; 178:1057-1065 (1993).
Luster, Andrew D., et al.; “The IP-10 Chemokine Binds to a Specific Cell Surface Heparan Sulfate Site Shared with Platelet Factor 4 and Inhibits Endothelial Cell Proliferation”; J. Exp. Med.; 182:219-231 (1995).
Luster, Andrew D., et al.; “γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins”; Nature; 315:672-676 (1985).
Qin, Shixin, et al.; “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions”; J. Clin. Invest.; 101(4):746-754 (1998).
Schall, Thomas J., et al.; “Hemokines, leukocyte trafficking, and inflammation”; Current Opinion in Immunology; 6:865-873 (1994).
Seitz, Michael, et al.;. “Enhanced Production of Neutrophil-activating Peptide-1/Interleukin-8 in Rheumatoid Arthritis”; Journal Clin. Invest.; 87:463-469 (1991).
Springer, Timothy A.; “Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration”; Annu. Rev. Physiol.; 57:827-872 (1995).
Taub, Dennis D., et al.; “Recombinant Human Interferon-inducible Protein 10 is a Chemoattractant for Human Monocytes and T Lymphocytes and Promotes T Cell Adhesion to Endothelial Cells”; The Journal of Experimental Medicine; 177:1809-1814 (1993).
Taub, Dennis D., et al.; “α and β Chemokines Induce NK Cell Migration and Enhance NK-Mediated Cytolysis”; The Journal of Immunol.; 155:3877-3888 (1995).
Uguccioni, Mariagrazia, et al.; “Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, Rantes, MIP-1α and MIP-1γ on human monocytes”; Eur. J. Immunol.; 25:64-68 (1995).
Wenshen Yu et al., U.S. Appl. No. 11/353,806; Notice of Allowance—mailed Aug. 24, 2009.
Preliminary Amendment for U.S. Appl. No. 12/519,970, submitted Jun. 18, 2009.
The Notice of Allowance and Fee(s) Due issued for U.S. Appl. No. 11/353,697 which published as U.S. Publication No. US2007/0021611.
Hobbs Douglas W.
Kozlowski Joseph A.
McGuinness Brian F.
Rosenblum Stuart B.
Shih Neng-Yang
Banerjee Krishna G.
Bernhardt Emily
Meade Erik A.
Pharmacopeia Inc.
Schering Corporation
LandOfFree
Heterocyclic substituted piperazine compounds with CXCR3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic substituted piperazine compounds with CXCR3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic substituted piperazine compounds with CXCR3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661384